首页> 美国卫生研究院文献>other >A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor MS-275 in Patients with Refractory Solid Tumors and Lymphomas

【2h】

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor MS-275 in Patients with Refractory Solid Tumors and Lymphomas

机译：难治性实体瘤和淋巴瘤患者口服组蛋白脱乙酰基酶抑制剂MS-275的I期和药代动力学研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

PurposeTo evaluate the toxicity profile, pharmacologic, and biological properties of 3-pyridylmethyl N-{4-[(2-aminophenyl)carbamoyl]benzyl}carbamate (MS-275), a histone deacetylase inhibitor, when administered orally on three different dosing schedules.

机译：目的评估口服组蛋白脱乙酰基酶抑制剂3-吡啶基甲基N- {4-[（（2-氨基苯基）氨基甲酰基]苄基}氨基甲酸酯（MS-275）的毒性特征，药理和生物学特性，按三种不同的给药方案口服给药。

著录项

期刊名称 other
作者
Lia Gore; Mace L. Rothenberg; Cindy L. OBryant; Mary Kay Schultz; Alan B. Sandler; Denise Coffin; Candice McCoy; Astrid Schott; Catherine Scholz; S. Gail Eckhardt;
展开▼
作者单位

展开▼
年(卷),期 -1(14),14
年度 -1
页码 4517
总页数 19
原文格式 PDF
正文语种
中图分类
关键词

相似文献

外文文献
中文文献
专利

1. A phase I and pharmacokinetic study of the oral histone deacetylase inhibitor, MS-275, in patients with refractory solid tumors and lymphomas. [J] . Gore L, Rothenberg ML, OBryant CL, Clinical cancer research: an official journal of the American Association for Cancer Research . 2008,第14期

机译：口服组蛋白脱乙酰基酶抑制剂MS-275在难治性实体瘤和淋巴瘤患者中的I期和药代动力学研究。
2. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. [J] . Ryan QC, Headlee D, Acharya M, Journal of Clinical Oncology . 2005,第17期

机译：组蛋白脱乙酰基酶抑制剂MS-275在患有晚期和难治性实体瘤或淋巴瘤的患者中的I期和药代动力学研究。
3. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors [J] . BanerjiU., VanDoornL., Papadatos-PastosD., Clinical cancer research: an official journal of the American Association for Cancer Research . 2012,第9期

机译：口服I类选择性组蛋白脱乙酰基酶抑制剂CHR-3996在难治性实体瘤中的I期药代动力学和药效学研究
4. Synthesis, Evaluation and Molecular Modeling Study of L-2-amino-7/8-Bromoalkanoic Acid Derivatives as Histone Deacetylase Inhibitors [C] . Dawei Huang, Xiaohui Li, Zhilong Xiu, Chinese international peptide symposium . 2011

机译：L-2-氨基-7 / 8-溴烷酸衍生物作为组蛋白脱乙酰酶抑制剂的合成，评价和分子建模研究
5. A phase I study of vincristine, escalating doses of irinotecan, temozolomide and bevacizumab (VIT-B) in pediatric and adolescent patients with recurrent or refractory solid tumors of non-hematopoietic origin [D] . Venkatramani, Rajkumar. 2010

机译：长春新碱，伊非替康，替莫唑胺和贝伐单抗（VIT-B）逐步剂量在患有非造血源性复发或难治性实体瘤的儿童和青少年患者中的I期研究
6. First-in-human Pharmacokinetic and Pharmacodynamic Phase I Study of Resminostat an Oral Histone Deacetylase Inhibitor in Patients with Advanced Solid Tumors [O] . André T. Brunetto, Joo Ern Ang, Rohit Lal, -1

机译：Resminostat（一种口服组蛋白去乙酰化酶抑制剂）在晚期实体瘤患者中的首次人体药代动力学和药效动力学I期研究
7. A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors [O] . Banerji, U. (Udai), Doorn, L. (Leni) van, Papadatos-Pastos, D. (Dionysis), 2012

机译：口服I类选择性组蛋白脱乙酰基酶抑制剂CHR-3996在难治性实体瘤中的I期药代动力学和药效学研究

A Phase I and Pharmacokinetic Study of the Oral Histone Deacetylase Inhibitor MS-275 in Patients with Refractory Solid Tumors and Lymphomas

摘要

著录项

相似文献

相关主题

期刊订阅